The scientific knowledge to produce insulin is widespread. The primary barrier to creating an affordable biosimilar is not a scientific challenge but raising sufficient capital to navigate manufacturing and distribution, a problem addressed by Project Insulin's non-profit, fundraising-first model.
An outsider's perspective, free from industry dogma, can be a powerful asset in life sciences. This viewpoint enables questioning of established norms and identifying unconventional solutions, such as applying a non-profit fundraising model to drug manufacturing.
High drug costs are systemic, rooted in the for-profit model's legal obligation to prioritize shareholder returns over patient affordability. This is compounded by a complex distribution chain where multiple middlemen—wholesalers, insurers, and pharmacies—each add a profit layer, inflating the final price.
To leverage modern, faster FDA pathways for biosimilars, robust analytical data demonstrating biosimilarity is critical. Therefore, a startup's choice of a Contract Development and Manufacturing Organization (CDMO) should hinge on their analytical expertise, which can reduce or eliminate the need for lengthy clinical trials.